1960 – Iberogast® is born
The original Iberogast® was developed in the late 1950s and went into production in 1960. At first, this was an extremely laborious process, as everything – including the extraction, mixing, bottling and packaging – was carried out by hand. Scientific research on the product intensified over the course of the 1960s.
1970s – production was optimised and clinical research initiated
In the 1960s, Iberogast® was launched as a pharmacy-only product, but already by the 1970s, it became obvious that decisive steps needed to be taken to expand and optimise production processes. As the decade was drawing to a close, the first clinical trials were conducted to demonstrate the product’s efficacy and tolerability, and the results were published.
1980s - Multi action effect discovered
In the early 1980s, the collaboration with one of the most renowned pharmacologist of the time, Professor Ammon of the University of Tübingen, was initiated. In 1986, this intense preclinical research cooperation led to the discovery of a key feature of Iberogast®: its dual mode action. The different effects of the medicine on the gastrointestinal tract – relaxation on the one hand and stimulation on the other – prompted a spate of further research activities and publications. From the mid-1980s, extensive research was carried out on Iberogast® to further demonstrate also its safety profile. Additionally, Iberogast® started to be marketed internationally for the first time in the 1980s.
1990s – Multi-target effect is discovered
By the late 1990s, the results of many safety and efficacy studies had been published. The design of all studies followed the latest scientific guidelines and met the current requirements for newly approved medications after the international guidelines of the ICH (International Conference on Harmonization for GCP — Good Clinical Practice). All of these early studies demonstrated that Iberogast® is well tolerated and effective in relieving gastrointestinal symptoms of Functional Dyspepsia and Irritable Bowel Syndrome.
2000s – positive effect on IBS shown
At the dawn of the new millennium, researchers described the significance of Iberis amara, as well as the mutually reinforcing effects of the individual medicinal plant extracts. The year 2003 proved to be especially crucial due to the discovery of the specific effects of Iberogast® on various parts of the stomach: the relaxing impact on the upper part of the stomach that stores food and the stimulating impact on the lower part of the stomach that transports food. Understandably, the findings stirred up considerable interest within the medical community. In 2007, a clinical trial confirmed this region-specificity of Iberogast® on different parts of the stomach in humans. In 2004, researchers described the product’s favourable mode of action in Irritable Bowel Syndrome and Functional Dyspepsia. In 2006, the multiple effects of Iberogast® were finally summarised as the multi-target principle and this description is valid ever since. Numerous investigations on further modes of action followed substantiating the multi-target principle.
2010s – Iberogast® in the fast lane
Results from the latest non-interventional study in 2013 confirmed the rapid onset of action of Iberogast® that starts working within 15 to 30 minutes. No other herbal remedy has been so well researched, and its mechanism of action is still the subject of studies carried out by numerous pharmacological experts. During this year, Bayer also acquired Steigerwald Arzneimittelwerk. Iberogast® became part of Bayer's brand portfolio and started benefiting from the company's global expertise in pharmaceuticals.
2020 - 60 year anniversary
The year 2020 marks Iberogast’s 60 year anniversary. To this day, the product remains highly recommended by doctors as a effective, well-tolerated liquid for people struggling with functional digestive symptoms.